ZAI Lab Obtains Global Rights to Sanofi NSCLC Drug Candidate

ZAI Lab, an innovative Shanghai biotech, has in-licensed global rights to a novel Sanofi multi-kinase inhibitor aimed at non-small cell lung cancer and other oncology indications.  ZAI will assume responsibility for global development, manufacturing and commercialization of the molecule. The deal calls for ZAI to pay Sanofi development and regulatory milestones, along with tiered royalties from sales, though details of the agreement were not disclosed. More details.... Stock Symbol: (NYSE: SNY) Share this with colleagues: // //